Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

1.2K
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
1.2K
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

594
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
594
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

1.5K
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
1.5K
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

2.0K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
2.0K
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

1.3K
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
1.3K
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

2.0K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
2.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

LED Railway Signal Detection Rather Than Recognition is Affected by Both Refractive and Non-refractive Blur.

Ophthalmic & physiological optics : the journal of the British College of Ophthalmic Opticians (Optometrists)·2026
Same author

Tradipitant: A Novel Neurokinin-1 Receptor Antagonist for Motion Sickness.

American journal of therapeutics·2026
Same author

Analyzing the effect of neoadjuvant stereotactic ablative body radiotherapy on pancreatic tumor perfusion using computed tomography perfusion.

Frontiers in oncology·2026
Same author

Time to lithium: A case register study of lithium initiation in bipolar disorder.

Journal of psychopharmacology (Oxford, England)·2026
Same author

Risk of incident cardiovascular disease events among older Asian, Native Hawaiian, and Pacific Islander colorectal cancer survivors in the United States: a cohort study.

Cardio-oncology (London, England)·2026
Same author

Interventional Treatment Strategies for Headache and Facial Pain.

Physical medicine and rehabilitation clinics of North America·2025

Related Experiment Video

Updated: Apr 20, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.5K

Using beta-blockers to treat heart failure.

Timothy Nguyen1, Ahmed Shaheed, Srikanth Venigalla

  • 1Timothy Nguyen is an associate professor of pharmacy practice at Long Island University's Arnold and Marie Schwartz College of Pharmacy and Health Sciences in Brooklyn, N.Y., and an adjunct clinical pharmacology professor in Long Island University's PA program and at St. Peter's University in New Jersey. Ahmed Shaheed, Srikanth Venigalla, and Emanuel Mullokandov are doctor of pharmacy candidates at Long Island University. The authors have disclosed no potential conflicts of interest, financial or otherwise.

JAAPA : Official Journal of the American Academy of Physician Assistants
|November 25, 2014
PubMed
Summary

Four beta-blocker medications—bisoprolol, carvedilol, metoprolol, and nebivolol—enhance survival in patients diagnosed with systolic heart failure. This review details their use, including initiation and titration strategies for optimal patient outcomes.

More Related Videos

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K
Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

1.6K

Related Experiment Videos

Last Updated: Apr 20, 2026

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs
07:09

A Surgical Model of Heart Failure with Preserved Ejection Fraction in Tibetan Minipigs

Published on: February 18, 2022

2.5K
Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

11.1K
Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding
10:39

Rat Model of Right-Sided Cardiac Remodeling and Arrhythmia Using Pulmonary Artery Banding

Published on: August 30, 2024

1.6K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • Systolic heart failure (SHF) is a significant cause of morbidity and mortality.
  • Beta-blockers are a cornerstone therapy for SHF, improving patient survival and quality of life.

Purpose of the Study:

  • To review four specific beta-blocker medications: bisoprolol, carvedilol, metoprolol, and nebivolol.
  • To provide guidance on the initiation and titration of these agents for healthcare practitioners.

Main Methods:

  • Literature review of clinical trials and guidelines concerning beta-blocker use in SHF.
  • Synthesis of evidence regarding the efficacy and safety profiles of bisoprolol, carvedilol, metoprolol, and nebivolol.

Main Results:

  • These four beta-blockers have demonstrated efficacy in improving survival rates in patients with SHF.
  • Optimal patient benefit is achieved through careful initiation and dose titration tailored to individual patient tolerance and response.

Conclusions:

  • Bisoprolol, carvedilol, metoprolol, and nebivolol are essential therapeutic options for managing systolic heart failure.
  • Adherence to evidence-based initiation and titration protocols is crucial for maximizing the benefits of these beta-blockers in clinical practice.